[S02DA03, antipyrine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Antipyrine.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Sulfamethoxazole.]
[J01GA01, streptomycin, Sulfamethoxazole may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L01AD04, streptozocin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Streptozocin.]
[L04AA27, fingolimod, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulfamethoxazole.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01CG01, sulbactam, Sulfamethoxazole may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Sulfamethoxazole.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfamethizole.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Antithymocyte immunoglobulin (rabbit).]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Antilymphocyte immunoglobulin (horse).]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Sulfamethoxazole can be decreased when combined with Sulfinpyrazone.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Sulfamethoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Sulpiride.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mercaptopurine.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Sulfamethoxazole.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Sulfamethoxazole.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sulfamethoxazole.]
[B01AE07, dabigatran etexilate, Sulfamethoxazole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Sulfamethoxazole.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Sulfamethoxazole.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Sulfamethoxazole.]
[L04AX02, thalidomide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Sulfamethoxazole.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Tioguanine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Thiothixene.]
[G04BE06, moxisylyte, Sulfamethoxazole may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Sulfamethoxazole may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01ED01, timolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01AA12, tobramycin, Sulfamethoxazole may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Sulfamethoxazole.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Sulfamethoxazole.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Sulfamethoxazole.]
[N06AF04, tranylcypromine, The metabolism of Sulfamethoxazole can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sulfamethoxazole.]
[L01XF01, tretinoin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Sulfamethoxazole.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Sulfamethoxazole may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trifluridine.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sulfamethoxazole.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sulfamethoxazole.]
[D07AC02, fluclorolone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Sulfamethoxazole.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Trimethaphan.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Sulfamethoxazole.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Sulfamethoxazole.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Sulfamethoxazole.]
[L04AA26, belimumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Belimumab.]
[L01FX04, ipilimumab, Sulfamethoxazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Sulfamethoxazole.]
[R02AA14, oxyquinoline, Sulfamethoxazole may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Linagliptin.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Rilpivirine.]
[S01AA28, vancomycin, Sulfamethoxazole may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Ezogabine.]
[B01AF01, rivaroxaban, Sulfamethoxazole may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Sulfamethoxazole can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Sulfamethoxazole.]
[N06AX09, viloxazine, Sulfamethoxazole may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vindesine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Sulfamethoxazole.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C03BA10, xipamide, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Xipamide.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Pipemidic acid.]
[J05AF01, zidovudine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Zuclopenthixol.]
[J05AE02, indinavir, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sulfamethoxazole.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Sulfamethoxazole.]
[L01FX05, brentuximab vedotin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, Sulfamethoxazole may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Sulfamethoxazole may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Sulfamethoxazole.]
[R03DC01, zafirlukast, The metabolism of Sulfamethoxazole can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Sulfamethoxazole may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulfamethoxazole.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Drospirenone.]
[V03AC02, deferiprone, Sulfamethoxazole may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alemtuzumab.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Sulfamethoxazole.]
[L01EJ01, ruxolitinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Tolterodine.]
[J01DH04, doripenem, Sulfamethoxazole may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Rituximab.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Sulfamethoxazole.]
[S01FA01, atropine, Atropine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Sulfamethoxazole.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Sulfamethoxazole.]
[H02AB11, prednylidene, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Prednylidene.]
[B03XA04, peginesatide, Sulfamethoxazole may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemcitabine.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Sulfamethoxazole.]
[M03BX01, baclofen, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Baclofen.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemtuzumab ozogamicin.]
[A08AA11, lorcaserin, Sulfamethoxazole may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Carfilzomib.]
[L02BB04, enzalutamide, The serum concentration of Sulfamethoxazole can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Teriflunomide.]
[L04AA22, abetimus, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Sulfamethoxazole.]
[D02BA02, octinoxate, Sulfamethoxazole may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bendamustine.]
[N04BD02, rasagiline, Rasagiline may increase the hypoglycemic activities of Sulfamethoxazole.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Sulfamethoxazole.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Sulfamethoxazole.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Sulfamethoxazole.]
[V09IX04, fluorodeoxyglucose F18, Sulfamethoxazole may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Sulfamethoxazole.]
[H01CB05, pasireotide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Sulfamethoxazole.]
[V08CA11, gadofosveset, Sulfamethoxazole may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ponatinib.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Sulfamethoxazole.]
[A16AX08, teduglutide, Sulfamethoxazole may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Sulfamethoxazole.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Sulfamethoxazole may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Sulfamethoxazole.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.]
[L04AX07, dimethyl fumarate, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Gemifloxacin.]
[M04AB03, benzbromarone, Sulfamethoxazole may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Moxifloxacin.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Sulfamethoxazole.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Benzocaine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Pramlintide.]
[L03AA12, ancestim, Sulfamethoxazole may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Sulfamethoxazole.]
[L01EC02, dabrafenib, The serum concentration of Sulfamethoxazole can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Benzydamine.]
[L01EE01, trametinib, Sulfamethoxazole may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Sulfamethoxazole may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sulfamethoxazole.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Bepridil.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Lixisenatide.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C02KX04, macitentan, Sulfamethoxazole may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Sulfamethoxazole.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Sulfamethoxazole.]
[G03AC08, etonogestrel, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J05AP08, sofosbuvir, Sulfamethoxazole may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.]
[C01CA27, droxidopa, Sulfamethoxazole may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Sulfamethoxazole.]
[L04AA32, apremilast, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Apremilast.]
[L02BG02, formestane, Sulfamethoxazole may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Betamethasone.]
[S01ED02, betaxolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Sulfamethoxazole may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Bezafibrate.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Albiglutide.]
[L04AC11, siltuximab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Sulfamethoxazole.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Sulfamethoxazole.]
[L04AA33, vedolizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Sulfamethoxazole.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Sulfamethoxazole.]
[L01XH04, belinostat, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Idelalisib.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Sulfamethoxazole.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Sulfamethoxazole.]
[J01XA05, oritavancin, The metabolism of Sulfamethoxazole can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Sulfamethoxazole.]
[S03AA06, gentamicin, Sulfamethoxazole may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Olaparib.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Sulfamethoxazole.]
[B01AF03, edoxaban, Sulfamethoxazole may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Sulfamethoxazole.]
[L04AC10, secukinumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Palbociclib.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XH03, panobinostat, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Panobinostat.]
[N02BE01, acetaminophen, The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Sulfamethoxazole.]
[L01DC01, bleomycin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bleomycin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Sulfamethoxazole is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Sulfamethoxazole.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Sulfamethoxazole.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Sulfamethoxazole.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin degludec.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Sulfamethoxazole.]
[V03AB37, idarucizumab, Sulfamethoxazole may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be decreased when combined with Sulfamethoxazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Sulfamethoxazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sulfamethoxazole.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Sulfamethoxazole.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Sulfamethoxazole.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Sulfamethoxazole.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Acetohexamide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Sulfamethoxazole.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Sulfamethoxazole.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Alminoprofen.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Sulfamethoxazole.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Sulfamethoxazole.]
[L04AC13, ixekizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Sulfamethoxazole.]
[N05BA08, bromazepam, Sulfamethoxazole may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Sulfamethoxazole may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Sulfamethoxazole.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulfamethoxazole.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Sulfamethoxazole.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Sulfamethoxazole.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Sulfamethoxazole.]
[C03CA02, bumetanide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Bupivacaine.]
[C07AA19, bupranolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Sulfamethoxazole.]
[L02AE01, buserelin, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Artemether.]
[M02AA03, clofezone, Sulfamethoxazole may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Sulfamethoxazole.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Sulfamethoxazole.]
[L01XK03, rucaparib, The metabolism of Sulfamethoxazole can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Sulfamethoxazole.]
[L04AC12, brodalumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Sulfamethoxazole.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Sulfamethoxazole.]
[L04AA36, ocrelizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ocrelizumab.]
[A06AH05, naldemedine, Sulfamethoxazole may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sulfamethoxazole.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Sulfamethoxazole.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Sulfamethoxazole may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daclizumab.]
[J01XX08, linezolid, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Linezolid.]
[J05AF06, abacavir, Sulfamethoxazole may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N07XX13, valbenazine, Sulfamethoxazole may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Sulfamethoxazole.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Sulfamethoxazole.]
[N04BD03, safinamide, Safinamide may increase the hypoglycemic activities of Sulfamethoxazole.]
[L04AC14, sarilumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Sarilumab.]
[J01MA23, delafloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Delafloxacin.]
[L04AC16, guselkumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Sulfamethoxazole.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Sulfamethoxazole.]
[L01XH01, vorinostat, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Sulfamethoxazole.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Sulfamethoxazole.]
[C07AB07, bisoprolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Sulfamethoxazole can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Bopindolol.]
[L04AC02, basiliximab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Basiliximab.]
[L01BA03, raltitrexed, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Raltitrexed.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Budesonide.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Sulfamethoxazole.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Sulfamethoxazole.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Semaglutide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Ertugliflozin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Macimorelin.]
[L02BB05, apalutamide, Sulfamethoxazole may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Sulfamethoxazole.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Sulfamethoxazole.]
[B02BX08, avatrombopag, The metabolism of Sulfamethoxazole can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01GB14, plazomicin, Sulfamethoxazole may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Sulfamethoxazole can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Sulfamethoxazole may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Sulfamethoxazole can be decreased when combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Sulfamethoxazole.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Sulfamethoxazole.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Sulfamethoxazole.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Carbutamide.]
[N01BA04, chloroprocaine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Chloroprocaine.]
[D08AE05, chloroxylenol, Sulfamethoxazole may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Sulfamethoxazole.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Inotersen.]
[L04AA39, emapalumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Carmustine.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Sulfamethoxazole.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Amifampridine.]
[L04AA43, ravulizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Sulfamethoxazole.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Sulfamethoxazole.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Sulfamethoxazole.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Sulfamethoxazole.]
[L04AA42, siponimod, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Siponimod.]
[J01FA09, clarithromycin, Sulfamethoxazole may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[N06BA14, solriamfetol, Sulfamethoxazole may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Sulfamethoxazole.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Sulfamethoxazole.]
[H02AB14, cloprednol, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sulfamethoxazole.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Sulfamethoxazole.]
[L04AB01, etanercept, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Sulfamethoxazole can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Sulfamethoxazole.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Upadacitinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Entrectinib.]
[N07XX11, pitolisant, Sulfamethoxazole may increase the QTc-prolonging activities of Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Sulfamethoxazole.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Sulfamethoxazole.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Sulfamethoxazole.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin pork.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sulfamethoxazole.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Sulfamethoxazole.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Deflazacort.]
[L01FD01, trastuzumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trastuzumab.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Sulfamethoxazole.]
[G03AC09, desogestrel, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Sulfamethoxazole.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M09AX08, golodirsen, Sulfamethoxazole may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulfamethoxazole.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Sulfamethoxazole may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Sulfamethoxazole.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Sulfamethoxazole.]
[L04AA53, teprotumumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Teprotumumab.]
[M01AX21, diacetylrhein, The metabolism of Sulfamethoxazole can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Sulfamethoxazole.]
[L04AA38, ozanimod, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Sulfamethoxazole.]
[R02AA03, dichlorobenzyl alcohol, Sulfamethoxazole may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sulfamethoxazole.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Sulfamethoxazole.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Sulfamethoxazole.]
[L01XF03, bexarotene, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Sulfamethoxazole can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Sulfamethoxazole.]
[L01AA02, chlorambucil, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Chlorcyclizine.]
[D07XB03, fluprednidene, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluprednidene.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Droxicam.]
[V08CA05, mangafodipir, Sulfamethoxazole may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sulfamethoxazole.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfamethoxazole.]
[L04AA47, inebilizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Sulfamethoxazole.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Sulfamethoxazole.]
[L01FX15, belantamab mafodotin, Sulfamethoxazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Sulfamethoxazole can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of methemoglobinemia can be increased when Chloroquine is combined with Sulfamethoxazole.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Sulfamethoxazole.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Sulfamethoxazole.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Sulfamethoxazole.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Sulfamethoxazole.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Etofenamate.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Etofibrate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Sulfamethoxazole.]
[L01BB05, fludarabine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fludarabine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Sulfamethoxazole may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Voclosporin.]
[L01EX21, tepotinib, The metabolism of Sulfamethoxazole can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Sulfamethoxazole can be decreased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Fenbufen.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01MB07, flumequine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluocinolone acetonide.]
[S01JA01, fluorescein, Fluorescein may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N02BG07, flupirtine, Sulfamethoxazole may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Sulfamethoxazole.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Sulfamethoxazole.]
[L03AB10, peginterferon alfa-2b, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Sulfamethoxazole.]
[J01MB06, cinoxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Cinoxacin.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Sulfamethoxazole.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Sulfamethoxazole.]
[L04AA54, pegcetacoplan, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Sulfamethoxazole.]
[L04AA48, belumosudil, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Anifrolumab.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Sulfamethoxazole may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Sulfamethoxazole may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Sulfamethoxazole may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Sulfamethoxazole.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Sulfamethoxazole.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Gliquidone.]
[N06AX25, St. John's wort extract, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Sulfamethoxazole can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Sulfamethoxazole.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Sulfamethoxazole.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Sulfamethoxazole.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Sulfamethoxazole.]
[B06AX04, mitapivat, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Sulfamethoxazole.]
[N03AE01, clonazepam, Sulfamethoxazole may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Sulfamethoxazole.]
[C01EB24, mavacamten, The serum concentration of Sulfamethoxazole can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Clopamide.]
[L04AC22, spesolimab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Deucravacitinib.]
[A05BA08, glycyrrhizic acid, Sulfamethoxazole may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Sulfamethoxazole.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Granisetron.]
[N05AH02, clozapine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Sotagliflozin.]
[J01GB12, arbekacin, Sulfamethoxazole may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Sulfamethoxazole.]
[H01AC08, somatrogon, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Proquazone.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Sulfamethoxazole.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XB01, colistin, Sulfamethoxazole may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Desflurane.]
[A04AA03, tropisetron, Sulfamethoxazole may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Sulfamethoxazole.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Mecasermin.]
[L01BB07, nelarabine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Nelarabine.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin glargine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Desloratadine.]
[J05AB14, valganciclovir, Sulfamethoxazole may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Sulfamethoxazole may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Sulfamethoxazole may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Sulfamethoxazole may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Sulfamethoxazole may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Sulfamethoxazole may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Sulfamethoxazole.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfamethoxazole.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Sulfamethoxazole.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Emedastine.]
[N05BA10, ketazolam, Sulfamethoxazole may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Lacidipine.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Sulfamethoxazole.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Sulfamethoxazole.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Levocabastine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Sulfamethoxazole.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Sulfamethoxazole.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Lofexidine.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Lonazolac.]
[R06AX13, loratadine, Loratadine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Sulfamethoxazole.]
[A06AD01, magnesium carbonate, Sulfamethoxazole may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Sulfamethoxazole can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Mebeverine.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sulfamethoxazole.]
[C07AA14, mepindolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Adenosine.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sulfamethoxazole.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Cyclizine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Melperone.]
[L04AA15, alefacept, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alefacept.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Miglitol is combined with Sulfamethoxazole.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypoglycemic activities of Sulfamethoxazole.]
[S01XA18, cyclosporine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypoglycemic activities of Sulfamethoxazole.]
[N06BA07, modafinil, The metabolism of Sulfamethoxazole can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Sulfamethoxazole.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Sulfamethoxazole.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Sulfamethoxazole.]
[L01BC01, cytarabine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cytarabine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Sulfamethoxazole.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Sulfamethoxazole.]
[L01AX04, dacarbazine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dactinomycin.]
[G03XA01, danazol, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfamethoxazole.]
[L01DB02, daunorubicin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daunorubicin.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Sulfamethoxazole.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Sulfamethoxazole.]
[N07BB05, nalmefene, Sulfamethoxazole may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Sulfamethoxazole.]
[C07AB12, nebivolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Sulfamethoxazole.]
[C01DX16, nicorandil, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Nicorandil.]
[L02BB02, nilutamide, The metabolism of Sulfamethoxazole can be decreased when combined with Nilutamide.]
[M03AC11, cisatracurium, Sulfamethoxazole may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Sulfamethoxazole.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Sulfamethoxazole.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Sulfamethoxazole.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Sulfamethoxazole.]
[D07XC02, desoximetasone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Desoximetasone.]
[V04CH02, indigo carmine, Sulfamethoxazole may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Sulfamethoxazole.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Sulfamethoxazole.]
[S03BA01, dexamethasone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Sulfamethoxazole.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Sulfamethoxazole.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sulfamethoxazole.]
[B01AC04, clopidogrel, The metabolism of Sulfamethoxazole can be decreased when combined with Clopidogrel.]
[C01DA05, pentaerythritol tetranitrate, Sulfamethoxazole may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Sulfamethoxazole may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Sulfamethoxazole.]
[V03AH01, diazoxide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Diazoxide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Phenol.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Sulfamethoxazole.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Cinchocaine.]
[R05DA08, pholcodine, Sulfamethoxazole may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Sulfamethoxazole.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Phthalylsulfathiazole.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Pioglitazone.]
[L01DC04, ixabepilone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Sulfamethoxazole.]
[L01DB08, pirarubicin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pirarubicin.]
[C03CA03, piretanide, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Piretanide.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Sulfamethoxazole.]
[D07XC04, diflucortolone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Difluocortolone.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Sulfamethoxazole.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Sulfamethoxazole.]
[C01AA05, digoxin, Sulfamethoxazole may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C10AX09, ezetimibe, Ezetimibe may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pegaspargase.]
[C04AE04, dihydroergocristine, Sulfamethoxazole may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Sulfamethoxazole.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Sulfamethoxazole.]
[L04AX04, lenalidomide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Lenalidomide.]
[J05AE08, atazanavir, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Sulfamethoxazole.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Sulfamethoxazole.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Pramocaine.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Sulfamethoxazole.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Sulfamethoxazole.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Sulfamethoxazole may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Sulfamethoxazole may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Sulfamethoxazole can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Sulfamethoxazole.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Quinapril is combined with Sulfamethoxazole.]
[B01AC07, dipyridamole, Dipyridamole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Sulfamethoxazole.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Sulfamethoxazole.]
[S01XA23, sirolimus, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Sirolimus.]
[S01AX06, resorcinol, Sulfamethoxazole may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sulfamethoxazole.]
[L04AA23, natalizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Natalizumab.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Sulfamethoxazole.]
[S02AA12, rifamycin SV, The metabolism of Sulfamethoxazole can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Levocetirizine.]
[L04AA21, efalizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Efalizumab.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Ropivacaine.]
[J01MB01, rosoxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Sunitinib.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Sulfamethoxazole.]
[L01XG01, bortezomib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bortezomib.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Sulfamethoxazole.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulfamethoxazole.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Sulfamethoxazole.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Sulfamethoxazole.]
[L01DB01, doxorubicin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Sulfamethoxazole.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Sulfamethoxazole.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Droperidol.]
[A08AA10, sibutramine, Sulfamethoxazole may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, Simvastatin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Sulfamethoxazole.]
[A12CA02, sodium sulfate, Sulfamethoxazole may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Succinylsulfathiazole.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Sultopride.]
[N02CC01, sumatriptan, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sumatriptan.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Corticotropin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Temozolomide.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Sulfamethoxazole.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Sulfamethoxazole.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Terodiline.]
[C07AA16, tertatolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Tertatolol.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Emetine.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Sulfamethoxazole.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Sulfamethoxazole.]
[M01AG02, tolfenamic acid, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypoglycemic activities of Sulfamethoxazole.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sulfamethoxazole.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Toremifene.]
[C03CA04, torsemide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Torasemide.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Sulfamethoxazole.]
[N05CC01, chloral hydrate, Sulfamethoxazole may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[H02CA01, trilostane, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trilostane.]
[L02AE04, triptorelin, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Triptorelin.]
[L01AA07, trofosfamide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trofosfamide.]
[J01MA04, enoxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Enoxacin.]
[L01CA04, vinorelbine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vinorelbine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Sulfamethoxazole.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Sulfamethoxazole.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Sulfamethoxazole.]
[C08CA12, mepirodipine, The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Sulfamethoxazole.]
[S01EA01, epinephrine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Epirubicin.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Sulfamethoxazole.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Zomepirac.]
[N03AX15, zonisamide, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Sulfamethoxazole.]
[L01XA02, carboplatin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Carboplatin.]
[C02AC02, guanfacine, Sulfamethoxazole may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Sulfamethoxazole.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Sulfamethoxazole.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Valproic acid.]
[L03AX05, pidotimod, Sulfamethoxazole may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N05CD04, estazolam, Sulfamethoxazole may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[G03CA03, estradiol, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Estradiol.]
[L01XX11, estramustine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluticasone.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sulfamethoxazole.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Sulfamethoxazole.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01CB01, etoposide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Etoposide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Sulfamethoxazole.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Sulfamethoxazole.]
[J01MA08, fleroxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Sulfamethoxazole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Terfenadine.]
[P01AX07, trimetrexate, Sulfamethoxazole may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Bupropion can be decreased when combined with Sulfamethoxazole.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Sulfamethoxazole.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Encainide.]
[L02AE02, leuprolide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Leuprolide.]
[L04AA02, muromonab-CD3, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Muromonab.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Sulfamethoxazole may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, Sulfamethoxazole may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dexrazoxane.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulfamethoxazole.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Sulfamethoxazole.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Sulfamethoxazole.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Sulfamethoxazole.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Sulfamethoxazole.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sulfamethoxazole.]
[L01BB06, clofarabine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cladribine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[G04BD02, flavoxate, Sulfamethoxazole may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Sulfamethoxazole can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Floctafenine.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fludrocortisone.]
[V03AB25, flumazenil, Sulfamethoxazole may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Flumethasone.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Sulfamethoxazole.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Sulfamethoxazole.]
[D07AC08, fluocinonide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluocinonide.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Sulfamethoxazole.]
[H02AB03, fluocortolone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluocortolone.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Sulfamethoxazole.]
[L01BC09, floxuridine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluorometholone.]
[L01BC02, fluorouracil, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sulfamethoxazole.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Sulfamethoxazole.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Flupentixol.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Sulfamethoxazole.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Sulfamethoxazole.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Sulfamethoxazole.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Sulfamethoxazole.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01BC03, tegafur, Sulfamethoxazole may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[G01AX06, furazolidone, Furazolidone may increase the hypoglycemic activities of Sulfamethoxazole.]
[J05AE10, darunavir, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Furosemide.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Sulfamethoxazole.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Sulfamethoxazole.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sulfamethoxazole.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Sulfamethoxazole.]
[C10AB04, gemfibrozil, The metabolism of Sulfamethoxazole can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dasatinib.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Sulfamethoxazole.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Sulfamethoxazole.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Methsuximide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Lapatinib.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Glipizide.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Sulfamethoxazole.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Sulfamethoxazole.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Sulfamethoxazole.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Sulfamethoxazole.]
[L01EX02, sorafenib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sulfamethoxazole.]
[M01CB04, aurothioglucose, Sulfamethoxazole may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Sulfamethoxazole may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Sulfamethoxazole.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Sulfamethoxazole.]
[S01EX01, guanethidine, Sulfamethoxazole may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sulfamethoxazole.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Haloperidol.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Sulfamethoxazole.]
[L02AE05, histrelin, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Sulfamethoxazole may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin aspart.]
[L01CE02, irinotecan, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Irinotecan.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Sulfamethoxazole.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Sulfamethoxazole.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Sulfamethoxazole.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Altretamine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Sulfamethoxazole.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Sulfamethoxazole.]
[C08CA10, nilvadipine, The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Sulfamethoxazole.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Sulfamethoxazole.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Sulfamethoxazole.]
[C02DB02, hydralazine, Sulfamethoxazole may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Hydrocortisone butyrate.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Sulfamethoxazole.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Sulfamethoxazole.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Sulfamethoxazole.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Sulfamethoxazole.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[G04BD06, propiverine, Sulfamethoxazole may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Sulfamethoxazole may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Hydroxyzine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Sulfamethoxazole.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Sulfamethoxazole.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Sulfamethoxazole.]
[B05XA08, sodium acetate, Sulfamethoxazole may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ifosfamide.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Sulfamethoxazole.]
[N06AA02, imipramine, Imipramine may decrease the hypoglycemic activities of Sulfamethoxazole.]
[L01CD01, paclitaxel, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Sulfamethoxazole.]
[L01CE01, topotecan, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Topotecan.]
[C03BA11, indapamide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Indomethacin.]
[A11HA07, inositol, Sulfamethoxazole may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Sulfamethoxazole.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Cyclopentamine.]
[S01XA28, varenicline, Sulfamethoxazole may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Sulfamethoxazole.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Sulfamethoxazole.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Sulfamethoxazole.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Vildagliptin.]
[C10AA06, cerivastatin, Cerivastatin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Anagrelide.]
[C07AA01, alprenolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Quinethazone.]
[L03AB09, interferon alfacon-1, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfacon-1.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Sulfamethoxazole.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Sulfamethoxazole.]
[N06AF05, iproniazid, The metabolism of Sulfamethoxazole can be decreased when combined with Iproniazid.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypoglycemic activities of Sulfamethoxazole.]
[P01AX06, atovaquone, The metabolism of Sulfamethoxazole can be decreased when combined with Atovaquone.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Sulfamethoxazole.]
[J04AC01, isoniazid, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Sulfamethoxazole may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Isosorbide dinitrate is combined with Sulfamethoxazole.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Sulfamethoxazole.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Sulfamethoxazole.]
[S01AA24, kanamycin, Sulfamethoxazole may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Sulfamethoxazole.]
[L04AC07, tocilizumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Sulfamethoxazole.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Sulfamethoxazole.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N05AH03, olanzapine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Ketoprofen is combined with Sulfamethoxazole.]
[L04AA24, abatacept, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mizolastine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sulfamethoxazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sulfamethoxazole.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Sulfamethoxazole.]
[A06AX03, lubiprostone, Sulfamethoxazole may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Sulfamethoxazole.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Etacrynic acid.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01DC03, mitomycin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mitomycin.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Lidoflazine.]
[S01AA21, amikacin, Sulfamethoxazole may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Sulfamethoxazole can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Sulfamethoxazole.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Sulfamethoxazole.]
[L01AD02, lomustine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Lomustine.]
[A07DA03, loperamide, The risk or severity of hypoglycemia can be increased when Loperamide is combined with Sulfamethoxazole.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Sulfamethoxazole.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Sulfamethoxazole.]
[L01EG01, temsirolimus, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Sulfamethoxazole may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Sulfamethoxazole may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Sulfamethoxazole.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Sulfamethoxazole.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Mecamylamine.]
[L01AA05, mechlorethamine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Sulfamethoxazole.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Sulfamethoxazole.]
[C03BA05, mefruside, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Mefruside.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Dalteparin.]
[L01AA03, melphalan, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Melphalan.]
[N06DX01, memantine, Sulfamethoxazole may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Sulfamethoxazole.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Sulfamethoxazole.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Mepivacaine.]
[G04BX16, tiopronin, Sulfamethoxazole may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Sulfamethoxazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mesoridazine.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Sulfamethoxazole.]
[N05AX13, paliperidone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Paliperidone.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Dolasetron.]
[H01CB03, lanreotide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Sulfamethoxazole.]
[N06BA03, methamphetamine, Sulfamethoxazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Sulfamethoxazole.]
[S01EC05, methazolamide, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Methazolamide.]
[J01XX05, methenamine, Methenamine can cause a decrease in the absorption of Sulfamethoxazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H03BB02, methimazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pemetrexed.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Sulfamethoxazole.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Sulfamethoxazole.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Sulfamethoxazole.]
[V04CG05, methylene blue, The metabolism of Sulfamethoxazole can be decreased when combined with Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Sulfamethoxazole.]
[H02AB04, methylprednisolone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sulfamethoxazole.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Sulfamethoxazole.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Sulfamethoxazole.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Metoclopramide.]
[C03BA08, metolazone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Sulfamethoxazole.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S02AA13, miconazole, The metabolism of Sulfamethoxazole can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Sulfamethoxazole.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Sulfamethoxazole.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Sulfamethoxazole.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Sulfamethoxazole can be decreased when combined with Valsartan.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Minocycline.]
[L01DB07, mitoxantrone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Sulfamethoxazole.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Sulfamethoxazole.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Ammonium chloride.]
[L04AA52, ofatumumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Mycophenolic acid.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sulfamethoxazole is combined with Raltegravir.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Sulfamethoxazole.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Sulfamethoxazole.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Sulfamethoxazole.]
[L03AB08, interferon beta-1b, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon beta-1b.]
[C07AA12, nadolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Sulfamethoxazole may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Sulfamethoxazole may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Sulfamethoxazole.]
[L04AC03, anakinra, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Sulfamethoxazole.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sulfamethoxazole.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01CD02, docetaxel, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Sulfamethoxazole.]
[S03AA01, neomycin, Sulfamethoxazole may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Sulfamethoxazole.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Levosimendan.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Sulfamethoxazole.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Sulfamethoxazole.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L03AX16, plerixafor, Sulfamethoxazole may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Sulfamethoxazole may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Sulfamethoxazole.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C01CE01, inamrinone, Sulfamethoxazole may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Amsacrine.]
[C10AD02, niacin, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypoglycemic activities of Sulfamethoxazole.]
[C08CA04, nicardipine, The metabolism of Sulfamethoxazole can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Sulfamethoxazole.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Nicotine.]
[C08CA05, nifedipine, Sulfamethoxazole may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Sulfamethoxazole.]
[C08CA07, nisoldipine, The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Sulfamethoxazole.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Nitric Oxide is combined with Sulfamethoxazole.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Nitroprusside is combined with Sulfamethoxazole.]
[N01AX13, nitrous oxide, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Nitrous oxide.]
[G03DC02, norethindrone, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Sulfamethoxazole.]
[R05DA07, noscapine, The metabolism of Sulfamethoxazole can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Sulfamethoxazole.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Reviparin.]
[H01CB02, octreotide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Ofloxacin.]
[L04AC04, rilonacept, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Sulfamethoxazole.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Sulfamethoxazole.]
[N02AA02, opium, Sulfamethoxazole may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A14AA08, oxandrolone, The metabolism of Sulfamethoxazole can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Oxprenolol.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Sulfamethoxazole.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Oxyphenbutazone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfamethoxazole.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Sulfamethoxazole.]
[N05AH05, asenapine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Danaparoid.]
[J04AB30, capreomycin, Sulfamethoxazole may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the hypoglycemic activities of Sulfamethoxazole.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01MA03, pefloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, Sulfamethoxazole may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Sulfamethoxazole.]
[M01CC01, penicillamine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Sulfamethoxazole may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[S01AA14, penicillin G, Sulfamethoxazole may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XX08, pentostatin, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pentostatin.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Perhexiline.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Sulfamethoxazole.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Phenazopyridine.]
[N06AF03, phenelzine, Phenelzine may increase the hypoglycemic activities of Sulfamethoxazole.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Sulfamethoxazole is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Sulfamethoxazole.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Sulfamethoxazole.]
[A08AA01, phentermine, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M02AA01, phenylbutazone, The metabolism of Sulfamethoxazole can be decreased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Sulfamethoxazole.]
[L04AB06, golimumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Sulfamethoxazole.]
[B02BA01, vitamin K1, Sulfamethoxazole may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Sulfamethoxazole.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Sulfamethoxazole.]
[C07AA03, pindolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Sulfamethoxazole.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J05AE01, saquinavir, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Pipotiazine.]
[N06BX03, piracetam, Sulfamethoxazole may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Sulfamethoxazole.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Sulfamethoxazole.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Sulfamethoxazole can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Sulfamethoxazole.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Sulfamethoxazole.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Sulfamethoxazole.]
[L04AC08, canakinumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Sulfamethoxazole.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Sulfamethoxazole.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin lispro.]
[C10AA08, pitavastatin, Sulfamethoxazole may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Prajmaline.]
[S03BA02, prednisolone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Sulfamethoxazole.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Primidone can be decreased when combined with Sulfamethoxazole.]
[M04AB01, probenecid, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Probucol.]
[C01BA02, procainamide, Sulfamethoxazole may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Procarbazine.]
[C10AB05, fenofibrate, Sulfamethoxazole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Prochlorperazine.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Sulfamethoxazole.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Sulfamethoxazole.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Sulfamethoxazole.]
[C07AA05, propranolol, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[B01AC09, epoprostenol, Sulfamethoxazole may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Sulfamethoxazole.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Sulfamethoxazole.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Sulfamethoxazole.]
[N07XX07, dalfampridine, Sulfamethoxazole may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Sulfamethoxazole may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Sulfamethoxazole.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Sulfamethoxazole.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Sulfamethoxazole.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sulfamethoxazole.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Sulfamethoxazole.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Rescinnamine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Sulfamethoxazole is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Sulfasalazine.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Sulfamethoxazole.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Sulfamethoxazole.]
[L01FA03, obinutuzumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Obinutuzumab.]
[J01GB08, sisomicin, Sulfamethoxazole may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Sulfamethoxazole may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Denosumab.]
[V04CC01, sorbitol, Sulfamethoxazole may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sulfamethoxazole.]
[L01CD04, cabazitaxel, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cabazitaxel.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Trimethoprim.]
[J01GA01, streptomycin, Trimethoprim may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Trimethoprim.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01CG01, sulbactam, Trimethoprim may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[S01AB01, sulfamethizole, The metabolism of Trimethoprim can be decreased when combined with Sulfamethizole.]
[J01EC03, sulfamoxole, The metabolism of Trimethoprim can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Trimethoprim can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Trimethoprim can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Trimethoprim can be decreased when combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Sulindac.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Trimethoprim.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Azapropazone.]
[L01BB02, mercaptopurine, Trimethoprim may increase the myelosuppressive activities of Mercaptopurine.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Trimethoprim.]
[L02BA01, tamoxifen, The metabolism of Trimethoprim can be decreased when combined with Tamoxifen.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L01CB02, teniposide, The metabolism of Trimethoprim can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Trimethoprim may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Trimethoprim may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Trimethoprim may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S03AA02, tetracycline, Trimethoprim may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[A04AD10, dronabinol, The metabolism of Trimethoprim can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Trimethoprim.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be decreased when combined with Trimethoprim.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Trimethoprim.]
[P02CA02, thiabendazole, Trimethoprim may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[G04BE06, moxisylyte, Trimethoprim may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Trimethoprim may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of hyperkalemia can be increased when Timolol is combined with Trimethoprim.]
[P01AB02, tinidazole, Trimethoprim may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Trimethoprim may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Trimethoprim may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Trimethoprim.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Tolmetin.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AF04, tranylcypromine, The metabolism of Trimethoprim can be decreased when combined with Tranylcypromine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Trimethoprim.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Triazolam.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Trimethoprim may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[A03AA05, trimebutine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Trimebutine.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Trimethoprim.]
[J01FA08, troleandomycin, The metabolism of Trimethoprim can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Trimethoprim may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Trimethoprim may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Trimethoprim may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Trimethoprim can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Trimethoprim can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Trimethoprim can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Trimethoprim can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Trimethoprim may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Trimethoprim may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Trimethoprim may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[B01AC24, ticagrelor, The metabolism of Trimethoprim can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Trimethoprim can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Trimethoprim can be decreased when combined with Viloxazine.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Vincristine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[B01AA03, warfarin, Trimethoprim may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Trimethoprim can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Trimethoprim.]
[J05AE02, indinavir, The metabolism of Trimethoprim can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Trimethoprim can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Trimethoprim.]
[M05BA05, tiludronic acid, Trimethoprim may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Trimethoprim may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Trimethoprim can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Trimethoprim can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Trimethoprim may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ibandronate.]
[N05AE04, ziprasidone, The metabolism of Trimethoprim can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Trimethoprim may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Trimethoprim may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Trimethoprim may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Trimethoprim may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The risk or severity of hyperkalemia can be increased when Atenolol is combined with Trimethoprim.]
[J02AC03, voriconazole, The metabolism of Trimethoprim can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Trimethoprim may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Trimethoprim.]
[B03XA04, peginesatide, Trimethoprim may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Trimethoprim may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Trimethoprim may increase the myelosuppressive activities of Azathioprine.]
[L01BC05, gemcitabine, Trimethoprim may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Trimethoprim.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Trimethoprim.]
[A08AA11, lorcaserin, Trimethoprim may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Trimethoprim may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[V03AX03, cobicistat, The metabolism of Trimethoprim can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Trimethoprim can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Trimethoprim can be decreased when it is combined with Enzalutamide.]
[L01EX05, regorafenib, The metabolism of Trimethoprim can be decreased when combined with Regorafenib.]
[D02BA02, octinoxate, Trimethoprim may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Trimethoprim can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Trimethoprim may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Trimethoprim.]
[V09IX04, fluorodeoxyglucose F18, Trimethoprim may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Trimethoprim.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Trimethoprim.]
[V08CA11, gadofosveset, Trimethoprim may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Trimethoprim.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Trimethoprim.]
[A16AX08, teduglutide, Trimethoprim may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Bencyclane.]
[A10BH04, alogliptin, Trimethoprim may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Trimethoprim may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Trimethoprim may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Trimethoprim.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[M04AB03, benzbromarone, The metabolism of Trimethoprim can be decreased when combined with Benzbromarone.]
[L03AA12, ancestim, Trimethoprim may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Trimethoprim.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Benzydamine.]
[L01EE01, trametinib, Trimethoprim may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Trimethoprim.]
[V09AX05, florbetapir F-18, Trimethoprim may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Trimethoprim.]
[C08EA02, bepridil, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Trimethoprim.]
[A10BJ03, lixisenatide, Trimethoprim may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Trimethoprim may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Trimethoprim.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J05AP05, simeprevir, The metabolism of Trimethoprim can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Trimethoprim may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Trimethoprim may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Acebutolol.]
[N05CH03, tasimelteon, Trimethoprim may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[A16AA07, metreleptin, The metabolism of Trimethoprim can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Trimethoprim can be increased when combined with Apremilast.]
[L02BG02, formestane, Trimethoprim may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Trimethoprim.]
[V03AB34, fomepizole, Trimethoprim may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Trimethoprim can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Trimethoprim can be decreased when combined with Ceritinib.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Trimethoprim.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Trimethoprim.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01XA05, oritavancin, The metabolism of Trimethoprim can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Trimethoprim.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Trimethoprim.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Trimethoprim.]
[B01AA01, dicumarol, The metabolism of Trimethoprim can be decreased when combined with Dicoumarol.]
[B01AF03, edoxaban, Trimethoprim may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[L04AC10, secukinumab, The metabolism of Trimethoprim can be increased when combined with Secukinumab.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Trimethoprim.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Acipimox.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Trimethoprim.]
[V03AB37, idarucizumab, Trimethoprim may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Trabectedin.]
[J02AC05, isavuconazole, The metabolism of Trimethoprim can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trimethoprim.]
[L01XG03, ixazomib, Trimethoprim may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Trimethoprim.]
[A10BB31, acetohexamide, The metabolism of Trimethoprim can be decreased when combined with Acetohexamide.]
[M04AB05, lesinurad, Trimethoprim may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Alminoprofen.]
[N03AX23, brivaracetam, Trimethoprim may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L01XX52, venetoclax, The metabolism of Trimethoprim can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Trimethoprim may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Trimethoprim may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C08CA01, amlodipine, The risk or severity of hyperkalemia can be increased when Amlodipine is combined with Trimethoprim.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Trimethoprim may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Trimethoprim.]
[N05BE01, buspirone, Trimethoprim may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, Trimethoprim may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Trimethoprim.]
[M02AA03, clofezone, Trimethoprim may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Trimethoprim.]
[L01XK03, rucaparib, The metabolism of Trimethoprim can be decreased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Trimethoprim can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Balsalazide.]
[A06AH05, naldemedine, Trimethoprim may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Trimethoprim may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C09AA07, benazepril, Trimethoprim may increase the hyperkalemic activities of Benazepril.]
[P01CA02, benznidazole, Trimethoprim may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J05AF06, abacavir, Trimethoprim may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Trimethoprim can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Trimethoprim may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Trimethoprim can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Trimethoprim can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Trimethoprim.]
[J01MA23, delafloxacin, Trimethoprim may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, The metabolism of Trimethoprim can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Trimethoprim.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Trimethoprim.]
[C07AB07, bisoprolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Trimethoprim can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Bopindolol.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Trimethoprim may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Bumadizone.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Trimethoprim.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Trimethoprim may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Trimethoprim may increase the hyperkalemic activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Trimethoprim can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Trimethoprim can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Trimethoprim.]
[C07AG02, carvedilol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Trimethoprim can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Trimethoprim can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Trimethoprim may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01GB14, plazomicin, Trimethoprim may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Trimethoprim.]
[L01XX62, ivosidenib, The metabolism of Trimethoprim can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Trimethoprim may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Trimethoprim can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Trimethoprim.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Trimethoprim.]
[D08AE05, chloroxylenol, Trimethoprim may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Lornoxicam.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L04AA39, emapalumab, The metabolism of Trimethoprim can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Trimethoprim.]
[A06AX05, prucalopride, Trimethoprim may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Trimethoprim may increase the hyperkalemic activities of Cilazapril.]
[B01AC23, cilostazol, Trimethoprim may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The metabolism of Trimethoprim can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Trimethoprim.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Trimethoprim.]
[J01FA09, clarithromycin, The metabolism of Trimethoprim can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The serum concentration of Solriamfetol can be increased when it is combined with Trimethoprim.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Trimethoprim.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ubidecarenone.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Trimethoprim can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Trimethoprim can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N07XX11, pitolisant, The serum concentration of Trimethoprim can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Trimethoprim.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trimethoprim.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[G03AC09, desogestrel, The metabolism of Trimethoprim can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Trimethoprim.]
[N03AX25, cenobamate, The serum concentration of Trimethoprim can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[M09AX08, golodirsen, Trimethoprim may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Trimethoprim may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Trimethoprim can be decreased when combined with Avapritinib.]
[M01AX21, diacetylrhein, The metabolism of Trimethoprim can be decreased when combined with Diacerein.]
[J05AE05, amprenavir, The metabolism of Trimethoprim can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Trimethoprim.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Trimethoprim.]
[R02AA03, dichlorobenzyl alcohol, Trimethoprim may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Trimethoprim may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02CC06, eletriptan, The metabolism of Trimethoprim can be decreased when combined with Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Trimethoprim can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Trimethoprim can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Trimethoprim can be decreased when combined with Dronedarone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Trimethoprim.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Droxicam.]
[V08CA05, mangafodipir, Trimethoprim may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Dexketoprofen.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Trimethoprim.]
[L04AC19, satralizumab, The serum concentration of Trimethoprim can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Trimethoprim.]
[L01EX23, pralsetinib, The metabolism of Trimethoprim can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA01, chlorpromazine, Trimethoprim may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.]
[A10BB02, chlorpropamide, Trimethoprim may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Ethenzamide.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Trimethoprim.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Etofenamate.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Etofibrate.]
[B06AC06, berotralstat, The metabolism of Trimethoprim can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Trimethoprim can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Trimethoprim may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Trimethoprim can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Trimethoprim can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Trimethoprim can be decreased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Fenbufen.]
[C01CA19, fenoldopam, Trimethoprim may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Trimethoprim may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Trimethoprim may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[N02BG07, flupirtine, Trimethoprim may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Trimethoprim.]
[L03AB10, peginterferon alfa-2b, The metabolism of Trimethoprim can be increased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Cimetidine.]
[V08CA04, gadoteridol, Trimethoprim may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Trimethoprim can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Trimethoprim can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Trimethoprim.]
[V09AB03, ioflupane I-123, Trimethoprim may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Trimethoprim may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Trimethoprim may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Mefenamic acid.]
[A10BB12, glimepiride, The metabolism of Trimethoprim can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Trimethoprim.]
[N06AX25, St. John's wort extract, The metabolism of Trimethoprim can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Trimethoprim can be decreased when combined with Asciminib.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Trimethoprim.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Clofibrate.]
[N01BB10, levobupivacaine, Trimethoprim may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA04, clomipramine, Trimethoprim may decrease the excretion rate of Clomipramine which could result in a higher serum level.]
[N03AE01, clonazepam, Trimethoprim may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[C01EB24, mavacamten, The serum concentration of Trimethoprim can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Trimethoprim.]
[N05AH02, clozapine, The metabolism of Trimethoprim can be decreased when combined with Clozapine.]
[J01GB12, arbekacin, Trimethoprim may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Trimethoprim can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Trimethoprim can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Proquazone.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Colchicine.]
[J01XB01, colistin, Trimethoprim may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Leflunomide.]
[A04AA03, tropisetron, Trimethoprim may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Trimethoprim may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Trimethoprim can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Indobufen.]
[J05AB14, valganciclovir, Trimethoprim may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[J05AF09, emtricitabine, Trimethoprim may decrease the excretion rate of Emtricitabine which could result in a higher serum level.]
[C05BB03, invert sugar, Trimethoprim may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Trimethoprim may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Trimethoprim may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Trimethoprim may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Trimethoprim may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Valdecoxib.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Trimethoprim.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Trimethoprim can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N05BA10, ketazolam, Trimethoprim may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Kebuzone.]
[L01EA01, imatinib, The metabolism of Trimethoprim can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Trimethoprim can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Lamotrigine.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Nafarelin.]
[N07BC04, lofexidine, Trimethoprim may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C09AA03, lisinopril, Trimethoprim may increase the hyperkalemic activities of Lisinopril.]
[A06AD01, magnesium carbonate, Trimethoprim may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Trimethoprim can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Mebeverine.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Mepindolol.]
[J01DH02, meropenem, Trimethoprim may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Cyclandelate.]
[R06AE03, cyclizine, The metabolism of Trimethoprim can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Trimethoprim may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.]
[S01XA18, cyclosporine, The metabolism of Trimethoprim can be decreased when combined with Cyclosporine.]
[N06BA07, modafinil, The metabolism of Trimethoprim can be decreased when combined with Armodafinil.]
[C09AA13, moexipril, Trimethoprim may increase the hyperkalemic activities of Moexipril.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Trimethoprim can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Cytarabine.]
[M01AH05, etoricoxib, The metabolism of Trimethoprim can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, Trimethoprim may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Trimethoprim can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Dantrolene.]
[J04BA02, dapsone, The serum concentration of Dapsone can be increased when it is combined with Trimethoprim.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Trimethoprim.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nabumetone.]
[N07BB05, nalmefene, Trimethoprim may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Trimethoprim.]
[C07AB12, nebivolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nebivolol.]
[S01GX04, nedocromil, Trimethoprim may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Trimethoprim can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nicorandil.]
[L02BB02, nilutamide, The metabolism of Trimethoprim can be decreased when combined with Nilutamide.]
[B01AX05, fondaparinux, Trimethoprim may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Olsalazine.]
[N06AA01, desipramine, Trimethoprim may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[V04CH02, indigo carmine, Trimethoprim may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Aliskiren.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Trimethoprim.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Oxaprozin.]
[S03BA01, dexamethasone, The metabolism of Trimethoprim can be increased when combined with Dexamethasone.]
[L04AB04, adalimumab, The metabolism of Trimethoprim can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Trimethoprim.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Trimethoprim.]
[N06AB05, paroxetine, The metabolism of Trimethoprim can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Trimethoprim can be decreased when combined with Clopidogrel.]
[C01DA05, pentaerythritol tetranitrate, Trimethoprim may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Trimethoprim may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Trimethoprim may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[R05DA08, pholcodine, Trimethoprim may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Trimethoprim.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[A03AA07, dicyclomine, Trimethoprim may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Trimethoprim may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Pinaverium.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Trimethoprim.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Trimethoprim.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Trimethoprim.]
[C08CA03, isradipine, The metabolism of Trimethoprim can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Trimethoprim may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Diflunisal.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Trimethoprim.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L04AX04, lenalidomide, Trimethoprim may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Trimethoprim can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Trimethoprim.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Trimethoprim.]
[V03AB04, pralidoxime, Trimethoprim may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[C08DB01, diltiazem, The metabolism of Trimethoprim can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Trimethoprim may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Trimethoprim may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Trimethoprim can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Trimethoprim.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Trimethoprim.]
[C09AA06, quinapril, Trimethoprim may increase the hyperkalemic activities of Quinapril.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Trimethoprim.]
[C09AA05, ramipril, Trimethoprim may increase the hyperkalemic activities of Ramipril.]
[S01AX06, resorcinol, Trimethoprim may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Trimethoprim can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Trimethoprim can be increased when combined with Rifapentine.]
[R06AE09, levocetirizine, Trimethoprim may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[A04AD12, aprepitant, The metabolism of Trimethoprim can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Trimethoprim can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Trimethoprim may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Trimethoprim.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C01CA07, dobutamine, Trimethoprim may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Trimethoprim.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Trimethoprim.]
[N06AA12, doxepin, Trimethoprim may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AB06, sertraline, The metabolism of Trimethoprim can be decreased when combined with Sertraline.]
[A08AA10, sibutramine, Trimethoprim may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Trimethoprim.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Trimethoprim.]
[A12CA02, sodium sulfate, Trimethoprim may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Trimethoprim may increase the hyperkalemic activities of Spirapril.]
[R03DA01, dyphylline, Trimethoprim may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Trimethoprim may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Trimethoprim may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Talinolol.]
[L01AX03, temozolomide, Trimethoprim may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Trimethoprim.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Tertatolol.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Tianeptine.]
[C09AA02, enalapril, Trimethoprim may increase the hyperkalemic activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Trimethoprim may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Trimethoprim.]
[C09AA10, trandolapril, Trimethoprim may increase the hyperkalemic activities of Trandolapril.]
[N05CC01, chloral hydrate, Trimethoprim may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C08CA12, mepirodipine, The metabolism of Trimethoprim can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The serum concentration of Epinephrine can be increased when it is combined with Trimethoprim.]
[C09AA15, zofenopril, Trimethoprim may increase the hyperkalemic activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Trimethoprim can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Trimethoprim.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C02AC02, guanfacine, Trimethoprim may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Iloprost.]
[N02CA02, ergotamine, The metabolism of Trimethoprim can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Trimethoprim can be decreased when combined with Valproic acid.]
[L03AX05, pidotimod, Trimethoprim may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Trimethoprim can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Trimethoprim may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Trimethoprim.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Trimethoprim.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Trimethoprim.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Ethosuximide.]
[M01AC06, meloxicam, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Meloxicam.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L04AD02, tacrolimus, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Tacrolimus.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Nizatidine.]
[R06AX12, terfenadine, The metabolism of Trimethoprim can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimethoprim may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Trimethoprim may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The metabolism of Trimethoprim can be decreased when combined with Fluvoxamine.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trimethoprim.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Trimethoprim.]
[M01CB01, gold sodium thiomalate, Trimethoprim may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Trimethoprim may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[A16AA01, levocarnitine, Trimethoprim may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Trimethoprim can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Fenoprofen.]
[N02AB03, fentanyl, Trimethoprim may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Trimethoprim may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Trimethoprim.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[G04BD02, flavoxate, Trimethoprim may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Trimethoprim can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Trimethoprim can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Trimethoprim may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Trimethoprim may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Trimethoprim.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Trimethoprim can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Trimethoprim.]
[N06AB03, fluoxetine, The metabolism of Trimethoprim can be decreased when combined with Fluoxetine.]
[N05CD01, flurazepam, Trimethoprim may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Fluspirilene.]
[L02BB01, flutamide, Trimethoprim may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[S02AA17, fosfomycin, Trimethoprim may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Trimethoprim.]
[J05AE10, darunavir, The metabolism of Trimethoprim can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Alendronic acid.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Trimethoprim.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The metabolism of Trimethoprim can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Trimethoprim may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[J05AG04, etravirine, The metabolism of Trimethoprim can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Methsuximide.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Trimethoprim.]
[A10BB01, glyburide, The metabolism of Trimethoprim can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Trimethoprim.]
[A10BB07, glipizide, Trimethoprim may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Trimethoprim may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[C01BD04, dofetilide, Trimethoprim may decrease the excretion rate of Dofetilide which could result in a higher serum level.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Trimethoprim.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Trimethoprim.]
[C07AB09, esmolol, The risk or severity of hyperkalemia can be increased when Esmolol is combined with Trimethoprim.]
[M01CB04, aurothioglucose, Trimethoprim may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Trimethoprim may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Trimethoprim.]
[C09AA09, fosinopril, Trimethoprim may increase the hyperkalemic activities of Fosinopril.]
[S01EX01, guanethidine, Trimethoprim may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Trimethoprim.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Trimethoprim.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Trimethoprim.]
[N05AH04, quetiapine, Trimethoprim may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Trimethoprim may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Heparin.]
[G03DC01, allylestrenol, Trimethoprim may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Trimethoprim.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Trimethoprim.]
[J05AG01, nevirapine, The metabolism of Trimethoprim can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Trimethoprim can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nimesulide.]
[C09AA04, perindopril, Trimethoprim may increase the hyperkalemic activities of Perindopril.]
[C02DB02, hydralazine, Trimethoprim may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Trimethoprim.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Trimethoprim.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[G04BD06, propiverine, Trimethoprim may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Trimethoprim.]
[B05AA07, hetastarch, Trimethoprim may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Risedronic acid.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Trimethoprim.]
[B05XA08, sodium acetate, Trimethoprim may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Trimethoprim.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Trimethoprim.]
[N06AA02, imipramine, Trimethoprim may decrease the excretion rate of Imipramine which could result in a higher serum level.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Trimethoprim.]
[R01AD07, tixocortol, Trimethoprim may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Trimethoprim.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Trimethoprim.]
[A11HA07, inositol, Trimethoprim may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The metabolism of Trimethoprim can be decreased when combined with Milnacipran.]
[S01XA28, varenicline, The serum concentration of Varenicline can be increased when it is combined with Trimethoprim.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Trimethoprim.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N05CH02, ramelteon, Trimethoprim may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Trimethoprim.]
[C07AA01, alprenolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Stavudine.]
[N06AF05, iproniazid, The metabolism of Trimethoprim can be decreased when combined with Iproniazid.]
[P01AX06, atovaquone, The metabolism of Trimethoprim can be decreased when combined with Atovaquone.]
[C09AA16, imidapril, Trimethoprim may increase the hyperkalemic activities of Imidapril.]
[J04AC01, isoniazid, The metabolism of Trimethoprim can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Trimethoprim may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Trimethoprim may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ivermectin.]
[S01AA24, kanamycin, Trimethoprim may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Trimethoprim.]
[L04AC07, tocilizumab, The metabolism of Trimethoprim can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Trimethoprim.]
[B01AC22, prasugrel, Trimethoprim may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Trimethoprim can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Trimethoprim can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Trimethoprim can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Ketoprofen.]
[L04AA24, abatacept, The metabolism of Trimethoprim can be increased when combined with Abatacept.]
[D10AX03, azelaic acid, Trimethoprim may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Labetalol.]
[N04BB01, amantadine, The serum concentration of Amantadine can be increased when it is combined with Trimethoprim.]
[A06AX03, lubiprostone, Trimethoprim may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Trimethoprim.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Lidoflazine.]
[S01AA21, amikacin, Trimethoprim may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Trimethoprim can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Trimethoprim.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Trimethoprim can be decreased when combined with Lovastatin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Trimethoprim.]
[B05XA11, magnesium chloride, Trimethoprim may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Trimethoprim may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Trimethoprim may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Trimethoprim can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Trimethoprim may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Trimethoprim may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Meclofenamic acid.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Trimethoprim.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Trimethoprim.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Dalteparin.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Trimethoprim.]
[N02AB02, meperidine, Trimethoprim may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Trimethoprim.]
[N01BB03, mepivacaine, Trimethoprim may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Trimethoprim may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Trimethoprim may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, The serum concentration of Metformin can be increased when it is combined with Trimethoprim.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06BA03, methamphetamine, Trimethoprim may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Trimethoprim.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, The metabolism of Trimethoprim can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Trimethoprim may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Trimethoprim is combined with Methotrexate.]
[D05BA02, methoxsalen, Trimethoprim may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Trimethoprim.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Methyldopa.]
[V04CG05, methylene blue, The metabolism of Trimethoprim can be decreased when combined with Methylene blue.]
[G03EK01, methyltestosterone, Trimethoprim may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Metoclopramide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The risk or severity of hyperkalemia can be increased when Metoprolol is combined with Trimethoprim.]
[P01AB01, metronidazole, The metabolism of Trimethoprim can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, Trimethoprim may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[S02AA13, miconazole, The metabolism of Trimethoprim can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Trimethoprim.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Parnaparin.]
[N05CD08, midazolam, Trimethoprim may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[G03XB01, mifepristone, The metabolism of Trimethoprim can be decreased when combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Tinzaparin.]
[J05AH01, zanamivir, Trimethoprim may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Valsartan.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Minocycline.]
[L01XX23, mitotane, The metabolism of Trimethoprim can be increased when combined with Mitotane.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Trimethoprim can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Trimethoprim.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Trimethoprim.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Trimethoprim can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Trimethoprim.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Trimethoprim.]
[L04AA06, mycophenolic acid, Trimethoprim may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Raltegravir.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Trimethoprim.]
[N03AB05, fosphenytoin, The serum concentration of Trimethoprim can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nadolol.]
[J01CA04, amoxicillin, Trimethoprim may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, The metabolism of Trimethoprim can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Trimethoprim can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Trimethoprim.]
[A10BG01, troglitazone, The metabolism of Trimethoprim can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, Trimethoprim may decrease the excretion rate of Duloxetine which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Letrozole.]
[S03AA01, neomycin, Trimethoprim may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The serum concentration of Repaglinide can be increased when it is combined with Trimethoprim.]
[B01AC17, tirofiban, Trimethoprim may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[L03AX16, plerixafor, Trimethoprim may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Trimethoprim may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Trimethoprim can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C01CE01, inamrinone, Trimethoprim may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Trimethoprim can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Trimethoprim.]
[C08CA05, nifedipine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of hyperkalemia can be increased when Nimodipine is combined with Trimethoprim.]
[C08CA07, nisoldipine, The risk or severity of hyperkalemia can be increased when Nisoldipine is combined with Trimethoprim.]
[C08CA08, nitrendipine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nitrofurantoin.]
[N05CF03, zaleplon, Trimethoprim may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Trimethoprim.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C01CA03, norepinephrine, The serum concentration of Norepinephrine can be increased when it is combined with Trimethoprim.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Trimethoprim can be increased when combined with Bosentan.]
[R05DA07, noscapine, The metabolism of Trimethoprim can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Reviparin.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Trimethoprim can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Trimethoprim.]
[N02AA02, opium, Trimethoprim may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, Trimethoprim may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[J01CF04, oxacillin, Trimethoprim may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[A14AA08, oxandrolone, The metabolism of Trimethoprim can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Trimethoprim may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[C07AA02, oxprenolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Oxprenolol.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Oxyphenbutazone.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Danaparoid.]
[J04AB30, capreomycin, Trimethoprim may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[G04BD11, fesoterodine, Trimethoprim may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Trimethoprim may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The metabolism of Trimethoprim can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Trimethoprim may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Trimethoprim may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Perhexiline.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Trimethoprim.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AF03, phenelzine, Trimethoprim may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[N03AA02, phenobarbital, The metabolism of Trimethoprim can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Trimethoprim.]
[V03AB36, phentolamine, Trimethoprim may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The metabolism of Trimethoprim can be decreased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The serum concentration of Trimethoprim can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Trimethoprim can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Trimethoprim may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Trimethoprim may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Mibefradil.]
[C07AA03, pindolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Trimethoprim.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Trimethoprim can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Trimethoprim may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Eprosartan.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Trimethoprim.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[J05AG02, delavirdine, The metabolism of Trimethoprim can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Trimethoprim.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Trimethoprim.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Trimethoprim.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Trimethoprim.]
[L04AC08, canakinumab, The metabolism of Trimethoprim can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Trimethoprim can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Trimethoprim may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Trimethoprim.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Trimethoprim.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Trimethoprim.]
[C07AB01, practolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Practolol.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Trimethoprim.]
[H02AB07, prednisone, Trimethoprim may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Trimethoprim can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Trimethoprim can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Trimethoprim can be decreased when combined with Probenecid.]
[C01BA02, procainamide, The excretion of Procainamide can be decreased when combined with Trimethoprim.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Fenofibrate.]
[G03DA04, progesterone, The metabolism of Trimethoprim can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Trimethoprim can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Trimethoprim can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Propafenone.]
[A03AB05, propantheline, Trimethoprim may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Trimethoprim.]
[C07AA05, propranolol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Propylthiouracil.]
[N02CC04, rizatriptan, Trimethoprim may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Trimethoprim may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Trimethoprim.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Trimethoprim.]
[P02CC01, pyrantel, Trimethoprim may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Trimethoprim.]
[P01BD01, pyrimethamine, The risk or severity of anemia can be increased when Pyrimethamine is combined with Trimethoprim.]
[C01BA01, quinidine, Trimethoprim may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Trimethoprim.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Trimethoprim.]
[C02AA01, rescinnamine, Trimethoprim may increase the hyperkalemic activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Reserpine can be increased when it is combined with Trimethoprim.]
[J05AP01, ribavirin, Trimethoprim may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Trimethoprim can be increased when combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Trimethoprim.]
[J01GB08, sisomicin, Trimethoprim may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Trimethoprim may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Trimethoprim may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
